GL Capital and Zylox-Tonbridge invest HK$1.48 billion in LifeTech Scientific
Lighthouse Two, a vehicle in which Zylox-Tonbridge holds 60%, subscribes for about 16.7% of LifeTech Scientific's enlarged share capital.
GL Capital and Zylox-Tonbridge Medical Technology said they will jointly invest about HK$1.482 billion in LifeTech Scientific through GL Lighthouse Two Investment Limited, which will subscribe for newly issued shares representing about 16.7% of LifeTech's enlarged share capital. Upon completion, Lighthouse Two will become LifeTech's largest single shareholder.
Zylox-Tonbridge will hold a 60% stake in Lighthouse Two for about HK$889 million. The companies said they may later buy additional LifeTech shares and that Zylox-Tonbridge intends to pursue a potential merger with LifeTech to build an integrated vascular and structural heart intervention platform in China.
LifeTech was established in 1999 in Shenzhen and sells aortic and structural heart devices, including left atrial appendage occluders. GL Capital is a China-focused healthcare investment firm founded in 2010.
Deal facts
- Target
- LifeTech Scientific
- Business
- Chinese medical device maker specializing in cardio-cerebrovascular and peripheral vascular interventions, with aortic and structural heart products
- Investor
- GL Lighthouse Two Investment Limited
- Sponsor
- GL Capital
- Deal type
- Minority stake
- Headquarters
- Shenzhen, China
- Value
- HK$1.482 billion
- Status
- Announced
- Announced
- Friday, November 6, 2026
Sources
- PR NewswireNov 6, 2026
Written by Buyout Desk from the sources above. Spotted an error? Email corrections@buyoutdesk.com.